The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
June 01, 2022
This publication discusses the use of Ninlaro (ixazomib)—a proteasome inhibitor—for the treatment of myeloma.
May 13, 2020
This publication discusses the use of Empliciti (elotuzumab)—a monoclonal antibody—for the treatment of myeloma.
June 29, 2022
Carvykti™ (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of adult…
April 20, 2022
This publication discusses the use of ABECMA® (idecabtagene vicleucel), the first CAR T-cell therapy to be approved by the FDA for patients with…
September 21, 2022
This publication covers monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
We Thank Our Sponsors:
BMS, GSK, Janssen, Karyopharm Therapeutics, Legend Biotech, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.